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Review
The CYP2B6 belongs to the family of Cytochrome P450 enzymes that catalyze the metabolism of a wide variety of drugs, including the
anti-retroviral EFV. The CYP2B6 gene, that has been mapped in the chromosome 19, is highly polymorphic and some SNP, namely
516G>T and 785A>G, are associated with decreased protein expression. These variants are related to phenotypes that are characterized
as EFV poor metabolizers, and consequently to episodes of neurotoxicity.
Objective
Identification and characterization of the major CYP2B6
polymorphisms in 48 HIV patients receiving antiretroviral therapy with
EFV.
Materials and Methods
Results
All the samples were classified as having the 785AG genotype.
Of all the 48 patients, 21 had the 516GG genotype and 27 has the
516TT genotype, table 1.
None of the SNP were in Hardy-Weinberg equilibrium which may
mean that the gene is evolving.
The genotype frequencies for the SNP 516G>T are the same among
males and females (p-value > 0.05), table 2.
The comparison of frequencies for the 516G>T by races also doesn't
show statistical significance, table 3.
Taking account to the results obtained, 27 subjects were classified as
being intermediate metabolizers and 21 as being poor or intermediate
metabolizers.
Conclusion
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Population Characteristics
Table:1 Genotype and allele frequencies of the CYP2B6 516G>T polymorphism
The sample was composed by 48 individuals infected with HIV-1
receiving ARV therapy with EFV. In terms of gender, 39 were male and
9 were female. Relatively to the race 39 were Caucasian and 9
African.
Table:2 Allele and genotype frequencies of CYP2B6 516G>T per gender.
SNP 516G>T
SNP 785A>G
SNP Genotype Male (%) Female (%) P-value
516G>T
GG 17 (36.2) 4 (8.5) 1
GT 22 (46.8) 5 (8.6)
G 56 (58.3) 13 (13.5) 1
T 22 (22.9) 5 (5.2)
SNP N  Genotype n  Freq.(%)  95% CI  P-value
516G>T
48 GG 21 43.75 (29.8,58.7) 0.007
GT 27 56.25 (41.3,70.2)
G 69 71.88 (61.6,80.4)
T 27 28.12 (19.7,38.4)
SNP  Genotype  Caucasian  (%) Negroid (%) P-value
516G>T
GG 17 (35.4) 4 (8.3) 1
GT 22 (45.8) 5 (10.4)
G 43 (52.44) 14 (17.07) 1
T 19 (23.17) 6 (7.32)
Table:3 Allele and genotype frequencies of CYP2B6 516G>T per races.
Haplotype SNP 516G>T SNP 785A>G Metabolizer
n
*1/*4 GG AG intermediate 27
*1/*6 GT AG intermediate
21
*6/*6 GT AG poor
Table 4: CYP2B6 haplotypes and their correspondence in terms of metabolism.
The study of the CYP2B6 gene variants is essential to provide information to complete the evalution of the impact of these polymorphisms
in ARV. 
There were no differences observed in the alellic and genotyping frequencies between genders and races. 
Of the 48 patients, 27 were classified has having the CYP2B6 *1/*4 haplotype (intermediate metabolizers) and 21 as having CYP2B6 *1/*6 
or *6/*6 haplotype (intermediate or poor metabolizers).
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